A Study of BGM0504 in Participants With Obesity

NCT06911203 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the investigational drug BGM0504 in adults who have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 90 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2025-04 · est. completion 2026-01

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06911203 ↗

Description as written by the study sponsor.

To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.

Treatments tested

BGM0504 Drug

Administered SC
Tirzepatide Drug

Administered SC

Main thing measured	Change From Baseline in Body Weight
Sponsor	BrightGene Bio-Medical Technology Co., Ltd.
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06911203 ↗